Home › Funds › Bellevue Group AG › AVLN
Bellevue Group AG position in AVLN
AVALYN PHARMA INC · Health Care
Bellevue Group AG reported holding 1,350,000 shares of AVLN (AVALYN PHARMA INC) in its Q2 2026 13F filing — a position valued at US$44.4M, representing 0.94% of its reported portfolio and ranking #31 among its reported holdings. Bellevue Group AG first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's AVLN position evolved
Bellevue Group AG first disclosed a stake in AVLN in Q2 2026 at 1,350,000 shares (US$44.4M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.35M | $44.44M | New |
About AVLN and 13F data
AVLN (AVALYN PHARMA INC) is a Health Care company. 97 other funds we track also report a position in AVLN — the largest reported positions include Novo Holdings A/S (US$127.8M), SR ONE CAPITAL MANAGEMENT, LP (US$108.9M), PERCEPTIVE ADVISORS LLC (US$88.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVLN
- Novo Holdings A/S 3.88M sh · $127.84M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 3.31M sh · $108.92M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.68M sh · $88.07M · Q2 2026
- MONTANOVA CAPITAL, LLC 2.50M sh · $82.40M · Q2 2026
- NVP Associates, LLC 2.27M sh · $74.68M · Q2 2026
- Catalio Capital Management, LP 1.68M sh · $55.17M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 966.79K sh · $31.83M · Q2 2026
- Andera Partners 929.82K sh · $26.49M · Q3 2026
- BRAIDWELL LP 801.39K sh · $26.38M · Q2 2026
- TPG GP A, LLC 773.07K sh · $25.45M · Q2 2026
- Rock Springs Capital Management LP 662.92K sh · $21.82M · Q2 2026
- Soleus Capital Management, L.P. 419.00K sh · $13.79M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held AVLN?
Bellevue Group AG has disclosed AVLN holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Bellevue Group AG's current position in AVLN?
As of Q2 2026, Bellevue Group AG holds 1.35M shares of AVLN (AVALYN PHARMA INC), valued at $44.44M, representing 0.94% of its reported portfolio and ranking #31.
Has Bellevue Group AG been buying or selling AVLN?
In the latest 13F filing (Q2 2026), Bellevue Group AG newly opened its position in AVLN.
Which other funds hold AVLN?
Other major institutional holders of AVLN include Novo Holdings A/S, SR ONE CAPITAL MANAGEMENT, LP, PERCEPTIVE ADVISORS LLC, among 97 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.